Abstract
Ultra-low temperature cryoablation (ULTC) is a novel ablation modality aiming to combine the effectiveness of surgical lesion delivery with percutaneous safety to improve outcomes in catheter ablations of atrial fibrillation, particularly in persistent AF (PsAF). In the Cryocure-2 study (NCT02839304) 78 patients (56.4% PsAF) received ULTC pulmonary vein isolation plus posterior wall ablation, and linear left and right atrial lesions as needed. The safety and acute success of ULTC appear consistent with current catheter ablation techniques and, together with Kaplan-Meier 85.9% 1-year freedom from AF observed in Cryocure-2 PsAF patients, warrant further evaluation in larger clinical trials, which are currently ongoing.
Original language | English (US) |
---|---|
Pages (from-to) | 1034-1039 |
Number of pages | 6 |
Journal | JACC: Clinical Electrophysiology |
Volume | 8 |
Issue number | 8 |
DOIs | |
State | Published - Aug 2022 |
Funding
All study-related costs were funded by Adagio Medical. Dr De Potter has received consulting fees from and owns equity options in Adagio Medical. Dr Babkin has served as a consultant and is a former employee of Adagio Medical. Dr Cox is co-founder and Director of Adagio Medical. Dr Boersma has received consulting fees from Adagio Medical. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Keywords
- atrial fibrillation ablation
- ultra-low temperature
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Physiology (medical)